The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese patients with mild to moderate atopic dermatitis.

Atopic dermatitis is a chronic, pruritic, inflammatory skin disease characterized by dry skin, erythema, oozing, crusting, and lichenification. Itchiness is a hallmark of the disease and a major burden for patients and their families. There are as many as 390 million patients with atopic dermatitis worldwide, and about 50 million patients in China, most of whom are mild and moderate patients. Current treatments primarily focus on alleviating symptoms (itching and dermatitis), preventing exacerbation of disease, and minimizing treatment risks. LNK01004 ointment is a topical, skin-restricted JAK inhibitor, primarily acting on the skin with rapid onset of action and minimal systemic exposure, thereby avoiding potential safety concerns associated with systemic drug exposure. It has the potential to be a first-in-class treatment with skin-restricted properties. LNK01004 ointment has completed Phase I clinical trials in healthy subjects, demonstrating a good safety profile. Phase Ib clinical trials for the treatment of psoriasis are currently underway.

Dr. Henry Wu, Chief Development Officer of Lynk Pharmaceuticals, said, "Atopic dermatitis is a chronic disease with a protracted course of symptoms. LNK01004 ointment has shown promising efficacy in preclinical studies, and good safety results in the healthy volunteer study. We believe it has the potential to be a better treatment for patients with atopic dermatitis. We are actively advancing the clinical development of this program and look forward to its performance in patient trials."